Fine Mapping of the $\textit{NRG1}$ Hirschsprung’s Disease Locus

Clara Sze-Man Tang$^{1,2,3}$, Wai-Kiu Tang$^{2,3}$, Man-Ting So$^{1,2}$, Xiao-Ping Miao$^{6}$, Brian Man-Chun Leung$^{2}$, Benjamin Hon-Kei Yip$^{1,2}$, Thomas Yuk-Yu Leon$^{2}$, Elly Sau-Wai Ngan$^{2,4}$, Vincent Chi-Hang Lui$^{2,4}$, Yan Chen$^{2}$, Ivy Hau-Yee Chan$^{2}$, Patrick Ho-Yu Chung$^{2}$, Xue-Lai Liu$^{2}$, Xuan-Zhao Wu$^{5}$, Kenneth Kak-Yuen Wong$^{2}$, Pak-Chung Sham$^{3,4}$, Stacey S. Cherry$^{1}$*, Paul Kwong-Hang Tam$^{2,4}$, Maria-Mercè Garcia-Barceló$^{2,4}$

1 Department of Psychiatry, University of Hong Kong, Hong Kong, China, 2 Department of Surgery, University of Hong Kong, Hong Kong, China, 3 Genome Research Centre, University of Hong Kong, Hong Kong, China, 4 Centre for Reproduction, Development and Growth, University of Hong Kong, Hong Kong, China, 5 Department of Surgery, Guiyang Medical College Affiliated Hospital, Guiyang, China, 6 Department of Epidemiology and Biostatistics, Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

Citation: Tang CS-M, Tang W-K, So M-T, Miao X-P, Leung BM-C, et al. (2011) Fine Mapping of the $\textit{NRG1}$ Hirschsprung’s Disease Locus. PLoS ONE 6(1): e16181. doi:10.1371/journal.pone.0016181

Editor: Florian Kronenberg, Innsbruck Medical University, Austria

Received September 17, 2010; Accepted December 7, 2010; Published January 20, 2011

Copyright: © 2011 Tang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by research grants from the Hong Kong Research Grants Council HKU 76560M to MGB and from The University of Hong Kong Seed Funding 20091159071 and 20081159006 to PT and MGB respectively. Support was also obtained from The University of Hong Kong Genomics Strategic Research Theme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: cherry@hku.hk (SSC); mmgarcia@hku.hk (MMGB)

† These authors contributed equally to this work.

Abstract

The primary pathology of Hirschsprung’s disease (HSCR, colon aganglionosis) is the absence of ganglia in variable lengths of the hindgut, resulting in functional obstruction. HSCR is attributed to a failure of migration of the enteric ganglion precursors along the developing gut. $\textit{RET}$ is a key regulator of the development of the enteric nervous system (ENS) and the major HSCR-causing gene. Yet the reduced penetrance of $\textit{RET}$ DNA HSCR-associated variants together with the phenotypic variability suggest the involvement of additional genes in the disease. Through a genome-wide association study, we uncovered a $\sim$350 kb HSCR-associated region encompassing part of the neuregulin-1 gene ($\textit{NRG1}$). To identify the causal $\textit{NRG1}$ variants contributing to HSCR, we genotyped 243 SNPs variants on 343 ethnic Chinese HSCR patients and 359 controls. Genotype analysis coupled with imputation narrowed down the HSCR-associated region to 21 kb, with four of the most associated SNPs ($\text{rs10088313, rs10094655, rs4624987, and rs3884552}$) mapping to the $\textit{NRG1}$ promoter. We investigated whether there was correlation between the genotype at the rs10088313 locus and the amount of $\textit{NRG1}$ expressed in human gut tissues (40 patients and 21 controls) and found differences in expression as a function of genotype. We also found significant differences in $\textit{NRG1}$ expression levels between diseased and control individuals bearing the same rs10088313 risk genotype. This indicates that the effects of $\textit{NRG1}$ common variants are likely to depend on other alleles or epigenetic factors present in the patients and would account for the variability in the genetic predisposition to HSCR.

Introduction

Hirschsprung’s disease (HSCR, aganglionic megacolon) is a congenital disorder of the enteric nervous system (ENS) characterised by the absence of enteric ganglia along a variable length of the intestine. There is significant ethnic variation in the incidence of the disease, and it is most often found among Asians (2.8 per 10,000 live births)[1,2]. Non-familial HSCR has a complex pattern of inheritance and manifests with low, sex-dependent penetrance and variability in the length of the aganglionic segment, according to which patients are classified into short segment (S-HSCR; 80%), long segment (L-HSCR; 15%), and total colonic aganglionosis (TCA; 5%). The male:female ratio is $\approx 4:1$ among S-HSCR patients and $\approx 1:1$ among L-HSCR patients. The recurrence risk to sibs of S-HSCR probands ranges between 1.5% and 3.3%, while risk to sibs of L-HSCR probands varies from 2.9% to 17.6%[1].

The $\textit{RET}$ gene, encoding a tyrosine-kinase receptor, is the major HSCR causing gene[3,4] and its expression is crucial for the development of the enteric ganglia. Mutations in the coding sequence (CDS) of $\textit{RET}$ account for up to 50% of the familial cases and between 15%–20% of the sporadic cases[5]. Other HSCR genes identified so far mainly code for protein members of interrelated signalling pathways involved in the development of enteric ganglia: $\textit{RET}$, endothelin receptor B (EDNRB), and the transcriptional regulator $\textit{SOX10}$[6–15]. Despite the importance of $\textit{RET}$, additional genes (acting either in conjunction with or independently from $\textit{RET}$) are necessary to explain not only the disease incidence but also its complex pattern of inheritance.

Through a genome-wide association study (GWAS) on Chinese individuals we identified the association of a 350 kb genomic region encompassing intron 1 of the $\textit{NRG1}$ gene with Hirsch-
As these intron 1 NRG1 HSCR-associated SNPs are not predicted to functionally affect the gene, we hypothesized that these loci are in linkage disequilibrium (LD) with a functional variant(s) not covered by the 500K Affymetrix chips used in our initial GWAS. To find those functional variant(s), we increased the genotype density within the region by genotyping 243 SNPs in 343 HSCR Chinese HSCR patients and 380 Chinese controls. Genotype imputation was used to further increase the SNPs density. As the NRG1 HSCR-associated region encompasses regulatory regions, we hypothesized that NRG1 SNPs could affect HSCR susceptibility by altering NRG1 expression. Thus, the difference between NRG1 expression levels in gut tissues of affected and non-affected individuals was tested, along with the relationship of expression with NRG1 genotype.

Results and Discussion

Fine mapping implicates the NRG1 promoter in HSCR susceptibility

Fine mapping of NRG1 was carried out by genotyping additional SNPs within the region delimited by the upstream and downstream recombination hot spots. We found 9 SNPs ("typed" in Table 1) more significantly associated with HSCR than rs7835688 (initially discovered in the GWAS, \( p = 5.92 \times 10^{-4} \); OR = 1.73 and 95% CI = 1.28 - 2.32 in this set) and one SNP with a \( p \)-value lower than that of the also GWAS identified rs16879552 (\( p = 8.99 \times 10^{-5} \); OR = 1.63 and 95% CI = 1.29 - 2.07; also in this set).

The SNP displaying the strongest association (rs10088313; in bold face in Table 1) mapped to the promoter region of most NRG1 isoforms, (except GGF2, associated with Schizophrenia[19]), and had the strongest LD (\( r^2 = 0.84 \)) with rs16879552. Other top SNPs were also in moderate to high LD with the previously GWAS-implicated SNPs (rs7835688 and rs16879552) (Figure 1, upper panel).

We next tried to refine our findings by imputing un-typed SNP allelic dosage using MACH. Imputation (based on HapMap Phase II haplotypes) nominated three additional HSCR-associated SNPs, rs10094655, rs4624987 and rs3884552, with highly similar level of association as rs16879552. In particular, rs3884552 displayed the highest significance level among all (Table 1). These markers fall again into the promoter of NRG1, about 10 kb upstream of rs16879552. Together with rs10088313, all five SNPs (rs10088313, rs10094655, rs4624987, rs3884552, and rs16879552) are highly correlated and have a similar MAF in both cases and controls. Beyond the region set by rs10088313 and rs16879552, we did not found any SNPs of similar levels of LD and significance. Thus, fine mapping coupled with imputation identified 5 highly associated SNPs (highlighted in grey in Table 1) narrowing-down the NRG1 associated region from 350 kb to 21.153 kb (Figure 1, lower panel). Haplotype analysis did not result in any haplotype appreciably more associated with HSCR than any single SNP.

As further genotyping and statistical genetic analysis of these 5 equally associated SNPs in an expanded sample would not help discern causality among these linked SNPs, we resorted to comparative genomics for the identification of conserved regulatory regions overlapping/neighbouring these loci as this would point at the functional SNP. Two conserved regions overlapping the two associated SNPs, rs10088313 and rs4624987 respectively, were observed (see Supplementary Figure S2). In particular, the region encompassing rs4624987 associates with signals of H3K1me1 and H3K27Ac chromatin activity, suggesting the presence of an enhancer. Importantly, rs4624987 falls in the vicinity of a transcription factor binding site (TFBS) for the transcription factor (TF) EVII (PhastCon 28-way score >0.93). No other described regulatory elements were identified. Even though the TFBS for EVII does not overlapped with rs4624987, the SNP associated allele might introduce a new site or reduce access to the predicted site located only a few base-pairs away. According to the literature reviewed, mice homozygous for targeted null Eei mutations are embryonic lethal and are characterized by widespread hypocellularity and poor/disrupted development of the cardiovascular and neural crest-derived cells[20].

As current data do not allow us to single out any of the four SNPs, we would argue that, most likely, they collectively represent a single signal of association and the lesser associated SNPs in the region are the aftermath of the indirect association. The fine-mapping of this NRG1 region may not been effective due to the high correlation among SNPs. Yet, the 350 kb region has been narrowed-down to a 21 kb region within which the most HSCR-associated NRG1 SNPs point at the NRG1 promoter as the culprit. Plausibly, the HSCR-associated alleles are bound to alter the regulation of NRG1 transcription and confer susceptibility to HSCR by affecting, in turn, the role of NRG1 signalling during ENS development.

HSCR-associated SNPs and NRG1 expression levels in human gut. If the NRG1 HSCR-associated SNPs identified in the promoter are functional (or in LD with a causal variant not discerned due to LD), they are likely to affect the gene expression. Thus, we next investigated whether there was a correlation between the genotypes of the NRG1 HSCR-associated SNPs and the levels of expression for this gene in human gut. Even though the causal variant cannot be pinpointed due to the high LD in the narrowed fine-mapped region, we assumed that the genotypes of the typed rs10088313 would represent those of the causal variant.

Due to alternative splicing, the NRG1 gene generates at least 3 main types (Type I, II and III) of proteins and at least 31 isoforms[19]. As each NRG1 type may have a different tissue-specific function, we assessed by RT-PCR which of the three main NRG1 types[15] was mainly expressed in human gut (data not shown). We detected expression of NRG1 Type I and vestigial expression of NRG1 type III (Sensory and Motor-neuron Derived Factor; SMDF; NM_013959.2). We did not detect expression of NRG1 type II. The feeble expression of NRG1 Type III detected in some samples may be due to the peripheral nervous system innervations of the gut, which is independent of the ENS.

In order to assess the effect of the NRG1 HSCR-associated SNPs on the expression of NRG1 type I in human gut, we used quantitative real-time PCR. We would also like to point out that as NRG1 is expressed in both intestinal mucosa and enteric ganglia[14], we did not discriminate between the different gut cellular types and assumed that the effect of the NRG1 regulatory SNPs would indiscriminately affect the total amount of NRG1 expressed in the gut.

The overall NRG1 expression in gut did not differ between patients and controls (\( F = 2.18, p = 0.15 \), two way ANOVA) as well as among genotypes for the combined samples (\( F = 0.29, p = 0.75 \)).
Table 1. Fine mapping association results of NRG1 SNPs using logistic regression on MACH-imputed allelic dosage

| SNP       | Position | MAPa,b | Allelec | Before imputation | Association values after imputation |
|-----------|----------|--------|---------|-------------------|-------------------------------------|
|           |          | Cases  | Controls| Type              | OR (95% CI)                     | p          |
| rs16879425| 32426748 | 0.44   | 0.34    | typed             | 2.29E-04                         | 1.57       | (1.23,1.99) | 2.21E-04 |
| rs10954845| 32439384 | 0.35   | 0.25    | typed             | 2.57E-04                         | 1.59       | (1.24,2.05) | 3.29E-04 |
| rs4422736 | 32490062 | 0.45   | 0.35    | typed             | 4.00E-04                         | 1.54       | (1.20,1.96) | 4.00E-04 |
| rs10113578| 32503670 | 0.51   | 0.40    | imputed           | NA                               | 1.53       | (1.22,1.94) | 3.18E-04 |
| rs10088313 | 32509603 | 0.52   | 0.40    | typed             | 6.71E-05                         | 1.60       | (1.27,2.02) | 6.71E-05 |
| rs10107065| 32510100 | 0.52   | 0.40    | imputed           | NA                               | 1.60       | (1.27,2.01) | 7.65E-05 |
| rs10113593| 32510900 | 0.51   | 0.40    | T                  | typed                            | 2.18E-04 | 1.55        | (1.23,1.96) | 2.04E-04 |
| rs10094655| 32513689 | 0.52   | 0.39    | T                  | imputed                          | NA       | 1.63       | (1.29,2.05) | 4.27E-05 |
| rs4624987 | 32516246 | 0.52   | 0.40    | G                  | imputed                          | NA       | 1.62       | (1.29,2.05) | 4.69E-05 |
| rs3884552 | 32519399 | 0.53   | 0.42    | T                  | imputed                          | NA       | 1.65       | (1.30,2.09) | 4.13E-05 |
| rs7826312 | 32519657 | 0.24   | 0.14    | T                  | typed                            | 3.22E-04 | 1.77        | (1.30,2.41) | 3.22E-04 |
| rs3802159 | 32524243 | 0.51   | 0.39    | G                  | typed                            | 1.25E-04 | NA         | NA         | NA       |
| rs7834206 | 32525690 | 0.27   | 0.16    | A                  | typed                            | 2.27E-04 | NA         | NA         | NA       |
| rs16879552| 32530758 | 0.51   | 0.38    | C                  | typed                            | 8.99E-05 | 1.63        | (1.29,2.07) | 4.19E-05 |
| rs7835688 | 32531041 | 0.26   | 0.15    | C                  | typed                            | 5.92E-04 | 1.73        | (1.28,2.32) | 3.00E-04 |
| rs16879576| 32560777 | 0.51   | 0.41    | A                  | imputed                          | NA       | 1.57       | (1.24,1.99) | 1.87E-04 |
| rs12680129 | 32562687 | 0.51   | 0.41    | A                  | typed                            | 1.86E-04 | 1.57        | (1.24,1.98) | 1.83E-04 |

Only SNPs with P-value lower than either or both of the 2 previously implicated SNPs (rs16879552 and rs7835688) are shown; a: minor allele frequency; underlined: SNPs found associated in the previously reported GWAS.

Significant interaction between genotype and case-control status (F = 5.54, p = 0.0064) was found, indicating that the relationship between genotype and expression level differs between cases and controls. When both groups (cases and controls) were stratified according to the rs10088313 genotypes (GG, GT, TT; risk allele in bold), post hoc pair-wise t-tests resulted in statistically significant differences among the three genotypes only within the control group (Figure 2). In this group, the highest NRG1 expression levels were observed in individuals with the GG (risk) genotype and the lowest in individuals with the TT genotype. Furthermore, GG in controls shows higher expression than GG in cases. These data suggest that the NRG1 risk allele has opposite effects on patients compared to controls. This may be explained by an additional susceptibility factor(s) (mainly present in the HSCR group) interfering with the role played by rs10088313 in NRG1 regulation. This allows us to hypothesize the presence of "transacting" elements that interact with NRG1 regulatory sites modulating their genetic effect on NRG1 transcription. In this context, patients’ specific mutations or polymorphisms in the gene encoding the predicted EVI-1 TF could account for the differences observed for the rs10088313 G allele. Another attractive hypothesis would be that the effect of the rs10088313 G allele was dependent on the RET risk alleles. This would be backed-up by our finding of genetic interaction between the RET rs2435357 (C/T) risk allele and the NRG1 risk alleles identified in our GWAS[14,21]. Importantly, while most of the controls with rs10088313 GG genotypes (N = 6) did not harbour the RET risk allele T (5 were CC and 1 CT for rs2435357), most patients with rs10088313 GG genotype (N = 11) had the RET risk allele T (7 were TT and 2 CT for rs2435357). We previously showed that this RET rs2435357T HSCR risk allele is associated with reduction of RET gene expression in gut tissues[22]. Thus, stratified analysis of NRG1 expression according to the RET rs2435357 genotypes would have helped elucidate if the reduction in RET expression relates to that of NRG1 and could perhaps account for the differences encountered in NRG1 expression between patients and controls with the same NRG1 genotype. We could not perform such stratified analysis as the sample size is not large enough and because the high frequency of the RET risk in the Chinese population prevents us from obtaining a large enough representation of all RET genotypes.

We have recently demonstrated that the RET rs2435357 T risk allele disrupts a SOX10 binding site that compromises RET transactivation[23] SOX10 is also known to regulate the expression of NRG1 receptor ErbB3 in neural crest cell receptors[15] Though the link between RET and NRG1 signalling in the development of the ENS is still to be elucidated our data suggests that NRG1 is player in the signaling network implicated in ENS development and maintenance and that may genetically and biologically interact with members of the RET signalling pathway during the ENS development. Biological interaction between RET and NRG1 signalling has been reported and linked to the survival and maintenance of the peripheral nervous system, where injury-induced expression of the RET ligand GDNF by non-myelinating Schwann cells is ErbB dependent[24].

We suspect that our expression data may be reflecting the result of the genetic NRG1-RET interaction previously described[14]. Somehow comparable findings have been reported in a study on NRG1 expression in post-mortem human brain samples of schizophrenic patients and control individuals where NRG1 expression levels differ between patients and controls for a given NRG1 schizophrenia susceptibility SNP genotype[25]. Collectively,
these findings warrant further study on NRG1 regulation and its implication in diseases.

This expression study has limitations, some of which cannot be overcome. Firstly, the gut of newborn patients is in an advanced developmental stage (although not fully mature). Thus our analysis does not mimic the expression of NRG1 during the early developmental stages of the human gut, when expression patterns of other genes may be different. For obvious reasons, this cannot be surmounted. Secondly, also for obvious reasons, it is not possible to obtain gut tissue samples from controls, requiring us to use samples from individuals who underwent gut biopsy for other motives than HSCR. Thirdly, the limited sample size is hampering the expression study. Again, it is difficult to obtain a balanced representation of all NRG1 SNP genotypes and a desirable number of gut tissues from affected and non-affected individuals.

We conclude that NRG1 regulatory SNPs may confer an increased risk of HSCR by interfering with the normal NRG1 expression in human developing gut and their effect is likely to depend on the genetic background of the individual, most likely DNA alterations on trans-acting regulatory proteins expressed in the developing gut in a time-specific manner or in other main

**Figure 1. Fine mapping association results of NRG1 SNPs.** Association results shown before (upper panel) and after imputation (lower panel). Diamonds and circles indicate genotyped and imputed SNPs respectively. Colour gradient (red $r^2 = 1$ to white $r^2 = 0$) marks the LD of the SNPs with rs10088313, except green for rs7835688, dark green for rs16879552 and blue for itself; grey indicates no information on LD. The 21 kb region we narrowed down to is highlighted in pink. The fine-scale recombination rate across the region is represented by the light-blue line. Green lines symbolize a schematic representation of the NRG1 isoforms overlapping the associated region. The bottom green line represents the GGF2 isoform associated with schizophrenia that expands 900 kb upstream the transcription start site for the rest of NRG1 isoforms.

doi:10.1371/journal.pone.0016181.g001

**Figure 2. NRG1 expression in human gut tissues.** Quantitative RT-PCR analysis of log-transformed expression ratio of NRG1 to 18S in the colon tissues from the normal portions of HSCR patients and non-HSCR patients stratified according to the rs10088313 (G/T; G risk allele). Bars represent the standard error (SE). $^* p<0.05$; $^{**} p<0.005$.

doi:10.1371/journal.pone.0016181.g002

HSCR genes such as RET. Why and how altered NRG1 expression may contribute to HSCR is yet to be learned.

**Materials and Methods**

**Ethics Statement**

At recruitment, informed consent was obtained from each subject. This study was approved by the institutional review board of the University of Hong Kong (UW 03-227 T/227).

**Subjects**

A total 343 ethnic Chinese patients diagnosed with sporadic HSCR were included for genotyping. Of those, 258 HSCR had been included in our previous GWAS[14] and 177 in the fine mapping of the 9q31 HSCR susceptibility locus[26]. The characteristics of the patients are summarized in supplementary Table S1.

Control individuals were obtained from the blood bank of the Hong Kong Red Cross. We included a total of 359 ethnic Chinese subjects without a diagnosis of HSCR.

Gut tissues were collected from 40 HSCR patients (subset of the 343 individuals genotyped) and 21 non-HSCR patients who had undergone colon surgery for reasons other than HSCR. For the 21 non-HSCR patients (12 affected with imperforate anus; 7 with necrotizing enterocolitis and 2 with mesenteric cysts), tissues were obtained from at least 2 cm away from the margin of the diseased bowel.

The HSCR diagnosis was histologically confirmed with either biopsy or surgical resection material for absence of enteric plexuses.

**SNP selection.** Following the identification of the NRG1 rs16879552 and rs7835688 HSCR-associated SNPs and the delimitation of the 350 kb HSCR-associated region (chromosome 9:32.235–32.575 Mb; hg18) as originally described, we proceeded with fine-mapping.

The 350 kb region is flanked by two major recombination hotspots (A: 32.235–32.245 Mb and C:32.565–32.575 Mb). A close-up look at the recombination rate within the region (downloaded from HapMap Phase II database) revealed an additional hotspot (B: 32.395–32.405 Mb) that disrupts slightly the LD of the main haplotype block (Supplementary Figure S1).

LD was found to be stronger in the region flanked by hotspots B and C. This B–C region spans from the 5' UTR to exon 2 of the NRG1 isoforms (except for isoform GGF2 -Gliaal Growth Factor; NM_013962.2) and includes mostly non-coding sequence DNA containing conserved noncoding elements (CNEs) which are likely
to control gene regulation, chromosome structure, and other key functions. Annotation and sequences of the DNA polymorphisms in the 350 kb region were downloaded from the NCBI dbSNP database (dbSNP129). Among the 2675 polymorphisms downloaded, we excluded 520 multiallelic variants and those known to be monomorphic SNPs in Asians. SNPs with MAF as low as 1% in HapMap were not excluded as we attempted to fine map the casual variant affecting the disease, which could be quite rare in the general population.

In order to minimize the genotyping cost, we used WCLUS-TAG[27], an in-house developed tagging program, to identify tag SNPs among the HapMap genotyped SNPs ($r^2>$0.90). For selection of SNPs without population frequencies available, we applied a tiered approach based on their functional significance: i) we force-included all nonsynonymous SNPs, since presumably they have higher impact on protein structure and function; and ii) we selected SNPs according to functional scores. For this, we relied on two databases, Ensembl and UCSC. The criteria for selection included accessibility to chromatin, CpG islands associated with promoter and the degree of conservation among species (Multiz 28-way). For each SNP, we also checked if the allelic variation introduces potential change in predicted transcription factor binding sites (TFBS). To this end, we used P-MATCH[28]. We assigned a higher score to SNPs among the HapMap genotyped SNPs ($r^2>$0.90).

For selection of SNPs without population frequencies available, we applied a tiered approach based on their functional significance: i) we force-included all nonsynonymous SNPs, since presumably they have higher impact on protein structure and function; and ii) we selected SNPs according to functional scores. For this, we relied on two databases, Ensembl and UCSC. The criteria for selection included accessibility to chromatin, CpG islands associated with promoter and the degree of conservation among species (Multiz 28-way). For each SNP, we also checked if the allelic variation introduces potential change in predicted transcription factor binding sites (TFBS). To this end, we used P-MATCH[28]. We assigned a higher score to SNPs among the HapMap genotyped SNPs ($r^2>$0.90).

Real-time assay for gene expression. Resected colon tissues were collected from 40 HSCR patients and 21 non-HSCR patients. No tissues were available from the rest of the patients. All resected tissues were immediately placed in liquid nitrogen and then stored at –80°C before analysis. Full-thickness tissues from ganglionic portions of bowel of each HSCR patient and colons from non-HSCR patients were used for RNA extraction by Trizol Reagent (Life Technologies, Rockville, MD) and converted to cDNA using an oligo (dT)15 primer and Superscript III (Invitrogen, Carlsbad, CA). The cDNA products equivalent to 10 ng of total RNA were used for quantitative real-time PCR which was performed by ready-to-use TaqMan gene expression assays from Applied Biosystems. The assay for NRG1 was Hs00247620 m1, which targets all but type 3 NRG1 SMDF (this isoform plays a major role in myelination). Real-time qPCR was performed in triplicate (96-well plates) on an ABI 7900 (Applied Biosystems) machine using standard thermal cycling conditions (10 min at 95°C, 40 cycles for 15 s at 95°C, 1 min at 60°C). A standard curve was constructed for each PCR run with 10-fold serial dilutions containing 100, 10, 1, 0.1 and 0.01 ng/mL of cDNA from the neuroblastoma cell line HTB11. The amount of target gene per sample was interpolated according to the standard curves. All analyses were performed in a blinded fashion with the laboratory operators unaware of genotyping data.

**Statistical analysis.** Association was assessed by means of R and PLINK[30] using logistic regression under an additive model and sample origin (Northern vs. Southern Chinese) was included as a covariate to correct for population stratification.

To further evaluate the association of untyped markers tagged by the genotyped SNPs, imputation was carried out by MACH[31] using HapMap Phase II CHB haplotypes as reference. As our ultimate goal here was to pinpoint the causal variant of $NRG1$, increasing marker density outweighed the use of the less dense yet more accurate Phase III panel.

We examined the effects of case-control status and $NRG1$ genotype on log-transformed $NRG1$ expression in gut via two-way ANOVA and post-hoc test of all pair-wise differences. These statistical analyses were done using R. All statistical tests were two-sided, and $p<0.05$ was considered significant.

**Supporting Information**

**Table S1** Characteristics of the Chinese HSCR patients included in the NRG1 genotyping. (DOCX)

**Figure S1** Schematic representation of the 350 kb $NRG1$ HSCR-associated region. On the top panel, close-up of the chromosome 8 association peak obtained in the GWAS. MIDDLE panel, recombination rates throughout the region (red vertical lines). $NRG1$ isoforms are represented by grey lines (boxes represent exons). Bottom line, Haploview representation of the LD in the region (D'). (TIF)

**Figure S2** Regional map of the 5 $HSCR$-associated SNPs. rs10088313, rs10094655, rs4624987, rs3884552 and rs16879552 depicted in top green panel, from left to right. Conservation information was given by PhastCon score for Multiz 28-way alignment for vertebrates [hg18]. (TIF)

**Author Contributions**

Conceived and designed the experiments: MMGB CSMT SST PCS PKHT. Performed the experiments: WKT MTS XPM BMCL TYYL. Analyzed the data: IHYC PHYC XLL XZW KKYW. Contributed reagents/materials/analysis tools: IHYC PHYC XLL XZW KKYW. Wrote the paper: CSMT SSC MMGB.

**References**

1. Amiel J, Sproat-Emison E, Garriga-Barcelo M, Lantieri F, Burzynski G, et al. (2008) Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet 45: 1–14.
2. Torik CP An epidemiological study of Hirschsprung disease in a multiracial California population. 1998; Evian, France.
3. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, et al. (1994) Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367: 378–380.
4. Hofstra RM, Valdenaire O, Arch E, Osinga J, Kroes H, et al. (1999) A loss-of-function mutation in the endothelin-converting enzyme 1 (ECE-1) associated with Hirschsprung disease patient. Nat Genet 14: 341–344.
5. Hofstra RM, Wu Y, Sulp RP, Ellrich P, Osinga J, et al. (2000) RET and GDINF gene scanning in Hirschsprung patients using two dual denaturing gel systems. Hum Mutat 15: 418–429.
6. Angrist M, Bolk S, Halushka M, Lapcak PA, Chakravarti A (1996) Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat Genet 14: 341–344.
7. Wrote the paper: CSMT SSC MMGB.
8. Pingault V, Bondurand N, Kuhlbrodt K, Goericke DE, Prehu MO, et al. (1998) SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 18: 171–173.
9. Brooks AS, Bertoli-Avella AM, Burzynski GM, Breedveld GJ, Oisingo J, et al. (2005) Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems. Am J Hum Genet 77: 120–126.
10. Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, et al. (1994) A missense mutation of the endothelin-B receptor gene in multigeneric Hirschsprung's disease. Cell 79: 1257–1266.
11. Hofstra RM, Oisingo J, Tan-Sindhunata G, Wu Y, Kamsteeg EF, et al. (1996) A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat Genet 12: 445–447.
12. Amiel J, Laudier B, Attie-Bitach T, Trang H, de Pontual L, et al. (2003) Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 33: 459–461.
13. Wakamatsu N, Yamada Y, Yamada K, Otsu T, Nomura N, et al. (2001) Mutations in SIP1, encoding Smad interacting protein-1, cause a form of Hirschsprung disease. Nat Genet 27: 369–370.
14. Garcia-Barcelo MM, Tang CS, Ngan ES, Lui VC, Chen Y, et al. (2009) Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease. Proc Natl Acad Sci USA 106: 2694–2699.
15. Britsch S (2007) The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 190: 1–65.
16. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, et al. (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev 12: 1825–1836.
17. Paratore C, Eichenberger C, Suter U, Sommer L (2002) Sox10 haploinsufficiency affects maintenance of progenitor cells in a mouse model of Hirschsprung disease. Hum Mol Genet 11: 3075–3085.
18. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, et al. (2006) Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proc Natl Acad Sci USA 103: 6747–6752.
19. Mei L, Xiong WC (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9: 437–452.
20. Wiser R (2007) The oncogene and developmental regulator EVII: expression, biochemical properties, and biological functions. Gene 396: 356–357.
21. Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, et al. (2005) A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. Nature 434: 357–360.
22. Miao X, Leon TY, Ngan ES, So MT, Yuan ZW, et al. (2010) Reduced RET expression in gut tissue of individuals carrying risk alleles of Hirschsprung's disease. Hum Mol Genet 19: 1461–1467.
23. Emison ES, Garcia-Barcelo M, Grice EA, Lantieri F, Amiel J, et al. (2010) Differential contributions of rare and common coding and noncoding ret mutations to multifactorial Hirschprung disease liability. Am J Hum Genet 87: 60–74.
24. Chen S, Liu C, Ji RR, Dikkes P, Coggeshall RE, et al. (2003) Disruption of ErbB receptor signaling in adult non-myelinating Schwann cells causes progressive sensory loss. Nat Neurosci 6: 1186–1193.
25. Ao SI, Yip K, Ng M, Cheung D, Fong PY, et al. (2005) A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. Nature 434: 357–360.
26. Tang CS, Subudian Y, Miao XP, de Vries AR, Burzynski G, et al. (2010) Fine mapping of the NR4A1 Hirschsprung's disease locus. Hum Genet.
27. Paratore C, Eichenberger C, Suter U, Sommer L (2002) Sox10 haploinsufficiency affects maintenance of progenitor cells in a mouse model of Hirschsprung disease. Hum Mol Genet 11: 3075–3085.
28. Chekmenev DS, Haid C, Kel AE (2005) P-Match: transcription factor binding site search by combining patterns and weight matrices. Nucleic Acids Res 33: W432–437.
29. Garcia-Barcelo MM, Miao X, Liu VC, So MT, Ngan ES, et al. (2007) Correlation Between Genetic Variations in Hox Clusters and Hirschsprung's Disease. Am J Hum Genet 71: 526–536.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet 81: 559–575.
31. Li Y, Miller C, Sanna S, Abecasis G (2009) Genotype imputation. Am J Hum Genet 80: 307–308.